Portal de Periódicos da CAPES

The localized rise of a B.1.526 SARS-CoV-2 variant containing an E484K mutation in New York State

2021; Cold Spring Harbor Laboratory; Linguagem: Inglês

10.1101/2021.02.26.21251868

Erica Lasek‐Nesselquist, Pascal Lapierre, Erasmus Schneider, Kirsten St. George, Janice D. Pata,

vaccines and immunoinformatics approaches

Abstract The E484K mutation in the spike protein of SARS CoV-2 contributes to immune escape from monoclonal antibodies as well as neutralizing antibodies in COVID-19 convalescent plasma. It appears in two variants of concern – B.1.351 and P.1 - but has evolved multiple times in different SARS-CoV-2 lineages, suggesting an adaptive advantage. Here we report on the emergence of a 484K variant in the B.1.526 lineage that has recently become prevalent in New York State, particularly in the New York City metropolitan area. In addition to the E484K mutation, these variants also harbor a D235G substitution in spike that might help to reduce the efficacy of neutralizing antibodies.